Canada markets open in 3 hours 22 minutes

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1273+0.0160 (+14.38%)
At close: 03:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1113
BidN/A x N/A
AskN/A x N/A
Day's Range0.1118 - 0.1273
52 Week Range0.0450 - 0.1905
Avg. Volume81,938
Market Cap40.935M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Cybin to Acquire Small Pharma Inc.

    - All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pend

  • GlobeNewswire

    Small Pharma Reports Fiscal First Quarter 2024 Highlights

    • Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date • SPL026 Phase IIa clinical trial results well-received at several international scientific conferences • Anticipated cash runway to at least Q4 2024 following recent operational restructuring LONDON, July 27, 2023 (GLOBE NEWSWI

  • GlobeNewswire

    Small Pharma Announces SPL028 R&D Strategy Update

    • Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024 • Implementation of ongoing operational efficiencies including a reduction in headcount of approximately one-third LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: